|
AnGes MG Announces Results of Phase II Clinical Trials of HGF Gene Medicine |
|
|
|
07 Jun 2006 |
TOKYO, Japon | Jun 06, 2006 | AnGes MG announced on June 5 the results of its phase II clinical trials of AMG0001, HGF (Hepatocyte Growth Factor) gene medicine.
Conducted in the US and intended to verify the efficacy and safety of AMG0001, the trials covered 104 patients with severe peripheral arterial disease. The results indicated that the administration of AMG0001 contributes to improving hemodynamics.
The drug tolerability proved to be good, and there were no safety problems.
Details of the trials were presented at the meeting of the Society for Vascular Medicine and Biology held in Philadelphia on June 3.
SOURCE: JCN |
